ASH 2018 | Outcomes of Hodgkin lymphoma patients who receive a second ASCT
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the latest EBMT Lymphoma Working Party registry study. This evaluated the outcome of relapsed/refractory Hodgkin lymphoma patients who received a second autologous stem cell transplantation (ASCT2). Dr Sureda highlights the key messages from this study; the time between transplants is the most important predictive factor for long-term outcomes.
Get great new content delivered to your inboxSign up